Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.54 |
| ▸ | CHRND | Q07001 | 5/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.53 |
| ▸ | CHRNG | P07510 | 1/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 2/20 | 0.53 |
| ▸ | NPY2R | P49146 | 2/20 | 0.53 |
| ▸ | NPY4R | P50391 | 2/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13076893 | 0.92 | TFPI (0.57) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL12589782 | 0.92 | TFPI (0.64) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL13076813 | 0.92 | TFPI (0.64) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL12589785 | 0.92 | TFPI (0.64) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL9523164 | 0.87 | TFPI (0.54) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL30569208 | 0.85 | TFPI (0.59) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL30168765 | 0.85 | TFPI (0.63) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL29757878 | 0.85 | NPY4R (0.58) | TFPIIL23RNPY1RNPY2RNPY4R | |
| SCHEMBL5049208 | 0.85 | NPY4R (0.59) | TFPINPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30567797 | 0.85 | TFPI (0.62) | TFPIIL23RNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130309277-A1 | POLYMER MICELLES CONTAINING ANTHRACYCLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2013-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309277-A1 | POLYMER MICELLES CONTAINING ANTHRACYCLINES FOR THE TREATMENT OF CANCER | TOP2B, TOP2A, ABCB4 | TFPI 4748/4885IL23R 3133/4885CHRND 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.